Released Feb 27, 2025, after the close
10-K filed Feb 28, 2025, 59 days after period end · 0001628280-25-008780
Q4 2024 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$57.48M$57.48M derived−1.3% vs Q4 2023+11.6% vs Q3 2024
Net Income$9.64M$9.64M derived+75.2% vs Q4 2023+924.7% vs Q3 2024
EPS, diluted—Not derived. Share counts vary by quarter.
Gross Profitderived$33,652,000+1.8%
Operating Incomederived$2,986,000N/M
Operating Cash Flowderived$1,997,000−79.0%
Free Cash Flowderived$1,103,000−86.2%
Margins · derived
Gross margin58.5%+1.8 pt vs Q4 2023
Operating margin5.2%+5.4 pt vs Q4 2023
Net margin16.8%+7.3 pt vs Q4 2023
What the release said
The release
Same quarter
| Metric | Q4 2024dderived from reported figures | Q4 2023dderived from reported figures | Q4 2022dderived from reported figures | Q4 2021dderived from reported figures |
|---|---|---|---|---|
| Revenue | $57.48M | $58.23M | $48.34M | $38.89M |
| Net Income | $9.64M | $5.50M | $3.72M | -$1.17M |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Cytek Biosciences, Inc. · CIK 1831915 · Engraved from SEC EDGAR